Biogen (BIIB) shares fell 5% after the biotech company said its Alzheimer’s drug diranersen would advance to Phase 3 trials despite failing the main goal of its Phase 2 study.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
